HIF1α genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC

Cellular Physiology and Biochemistry

Volumn 32, Issue 6, 2013, Pages 1566-1576

  Wu, Fenglei ^a   Zhang, Jian ^b   Liu, Yi ^a   Zheng, Yigong ^a   Hu, Nan ^a  

^a The First People s Hospital of Lianyungang City   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Hypoxia inducible factor 1 ; Non small cell lung cancer; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NAVELBINE; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT RESPONSE; NON SMALL CELL LUNG CANCER; TREATMENT OUTCOME;

AGED; ALLELES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COORDINATION COMPLEXES; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84893105677     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000356593     Document Type: Article

References (45)

1. Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
2. Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC: Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006; 51:303-311.
3. Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J: Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 2010;40:954-960.
4. Cui LH, Yu Z, Zhang TT, Shin MH, Kim HN, Choi JS: Influence of polymorphisms in MTHFR 677 CT, TYMS 3R2R and MTR 2756 AG on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics 2011;12:797-808.
5. Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, Wang L, Zhao N, Hu J, Lu D, Jin L, Li Q, Wang JC: Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res 2012;18:3972-3981.
6. Butkiewicz D, Drosik A, Suwinski R, Krzesniak M, Rusin M, Kosarewicz A, Rachtan J, Matuszczyk I, Gawkowska-Suwinska M: Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. Int J Cancer 2012;131:E1100-1108.
7. Yan PW, Huang XE, Yan F, Xu L, Jiang Y: Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev 2011;12:2291-2294.
8. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, Tsuta K, Nokihara H, Yamamoto N, Sekine I, Ohe Y, Tamura T, Yokota J, Kunitoh H.: Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28:4945-4952.
9. Vaupel P: Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
10. Chan DA, Giaccia AJ: Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007;26:333-339.
11. Chaudary N, Hill RP: Hypoxia and metastasis in breast cancer. Breast Dis 2006;26:55-64.
12. Krishnamachary B, Semenza GL: Analysis of hypoxia-inducible factor 1alpha expression and its effects on invasion and metastasis. Methods Enzymol 2007;435:347-354.
13. Tsai YP, Wu KJ: Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci 2012;19:102.
14. Kobayashi M, Nakagawa K: [Metastasis and hypoxia-inducible factor]. Gan To Kagaku Ryoho 2010;37:2047-2051.
15. Hou XW, Yang RQ, Zhong YG, Gao W, Sun SP, Wang NF: G501C polymorphism of the oxidized LDL receptor gene is associated with albuminuria in Chinese essential hypertension patients. Genet Mol Res 2011;10: [Epub ahead of print].
16. Chun YS, Kim MS, Park JW: Oxygen-dependent and -independent regulation of HIF-1alpha. J Korean Med Sci 2002;17:581-588.
17. Fang J, Yan L, Shing Y, Moses MA: HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 2001;61:5731-5735.
18. Raheja LF, Genetos DC, Wong A, Yellowley CE: Hypoxic regulation of mesenchymal stem cell migration: the role of RhoA and HIF-1alpha. Cell Biol Int 2011;35:981-989.
19. Semenza GL: Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012;33:207-214.
20. Monsef N, Soller M, Panagopoulos I, Abrahamsson PA: HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation. BMC Cancer 2010;10:385.
21. Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G.: Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009;115:3651-3660.
22. Schrijvers ML, van der Laan BF, de Bock GH, Pattje WJ, Mastik MF, Menkema L, Langendijk JA, Kluin PM, Schuuring E, van der Wal JE: Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:161-169.
23. Chen HH, Su WC, Lin PW, Guo HR, Lee WY: Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat 2007;103:167-175.
24. Sun L, Liu Y, Lin S, Shang J, Liu J, Li J, Yuan S, Zhang L: Early growth response gene-1 and hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of tissue factor. Acta Oncol 2013;52:842-845.
25. Monti E, Gariboldi MB: HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol 2011;4:62-77.
26. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
27. Vainrib M, Golan M, Amir S, Dang DT, Dang LH, Bar-Shira A, Orr-Urtreger A, Matzkin H, Mabjeesh NJ: HIF1A C1772T polymorphism leads to HIF-1alpha mRNA overexpression in prostate cancer patients. Cancer Biol Ther 2012;13:720-726.
28. Li P, Cao Q, Shao PF, Cai HZ, Zhou H, Chen JW, Qin C, Zhang ZD, Ju XB, Yin CJ: Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian J Androl 2012;14:864-869.
29. Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W, Feng X: RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS One 2012;7:e43734.
30. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
31. Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, Zhang W, Qian J, Wang J, Chen H, Wei Q, Han B, Lu D.: Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS One 2012;7:e33200.
32. Santo A, Genestreti G, Terzi A, Azzoni P, Sava T, Manno P, Molino A, Pattaro C, Micciolo R, Cetto GL: Gemcitabine (GEM) and vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): a phase II study in elderly or poor performance status patients. Lung Cancer 2006;53:355-360.
33. Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y: First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006;24:64-69.
34. Nava-Salazar S, Sanchez-Rodriguez EN, Mendoza-Rodriguez CA, Moran C, Romero-Arauz JF, Cerbon MA: Polymorphisms in the hypoxia-inducible factor 1 alpha gene in Mexican patients with preeclampsia: A case-control study. BMC Res Notes 2011;4:68.
35. Soini Y, Kahlos K, Puhakka A, Lakari E, Saily M, Paakko P, Kinnula V: Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. Br J Cancer 2000;83:880-886.
36. Mera-Menendez F, Hinojar-Gutierrez A, Guijarro Rojas M, de Gregorio JG, Mera-Menendez E, Sanchez JJ, Quintanilla M, Cerezo L, Gamallo C: Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx. Clin Transl Oncol 2013;15:358-363.
37. Zagouri F, Sergentanis TN, Gazouli M, Tsigginou A, Dimitrakakis C, Papaspyrou I, Eleutherakis-Papaiakovou E, Chrysikos D, Theodoropoulos G, Zografos GC,Antsaklis A, Dimopoulos AM, Papadimitriou CA: HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study. Mol Biol Rep 2012;39:10873-10879.
38. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J: Hypoxia-inducible factor-1alpha (HIF- 1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate 2007;67:1354-1361.
39. Havelund BM, Spindler KL, Ploen J, Andersen RF, Jakobsen A: Single nucleotide polymorphisms in the HIF- 1alpha gene and chemoradiotherapy of locally advanced rectal cancer. Oncol Lett 2012;4:1056-1060.
40. Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.
41. Xu HY, Hou XW, Wang LF, Wang NF, Xu J: Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem 2010;335:13-17.
42. Kim HO, Jo YH, Lee J, Lee SS, Yoon KS: The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncol Rep 2008;20:1181-1187.
43. Kuo WH, Shih CM, Lin CW, Cheng WE, Chen SC, Chen W, Lee YL: Association of hypoxia inducible factor- 1alpha polymorphisms with susceptibility to non-small-cell lung cancer. Transl Res 2012;159:42-50.
44. Wohlkoenig C, Leithner K, Deutsch A, Hrzenjak A, Olschewski A, Olschewski H: Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. Cancer Lett 2011;308:134-143.
45. Shioya M, Takahashi T, Ishikawa H, Sakurai H, Ebara T, Suzuki Y, Saitoh J, Ohno T, Asao T, Kuwano H, Nakano T: Expression of hypoxia-inducible factor 1alpha predicts clinical outcome after preoperative hyperthermo- chemoradiotherapy for locally advanced rectal cancer. J Radiat Res 2011;52:821-827.